Skip to main content
Premium Trial:

Request an Annual Quote

OpGen, Detroit Lab to Study Brain Tumor DNA

NEW YORK, Feb. 19 (GenomeWeb News) - OpGen will use its optical-mapping technology to help the HermelinBrainTumorCenterstudy oligodendrogliomas, the groups said today.


OpGen said it has begun an optical mapping study of the tumor that is aimed at helping researchers at Detroit-based Hermelin identify lesions in a tumor's genome "to determine what is happening at the DNA level and how well a patient will respond to treatment."


According to Oliver Bogler, an associate scientist at the HermelinCenter, deletions on chromosome 1p and 19q of the tumor "correlate strongly with response to a range of therapies," and that "it is crucial to understand the nature of these rearrangements."


"The fact that these deletions affect response to such different treatments, including various drug combinations and radiotherapy, indicates that something fundamental is going on here, and understanding these events could be crucial in developing new treatments for this, and possibly other lethal cancers," Bogler said in a statement.